| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| ACCOUNTING FEES | 4,590 | 3,442 | 1,148 |
| Name of Bond | End of Year Book Value | End of Year Fair Market Value |
|---|---|---|
| JP MORGAN CHASE BANK - BONDS | 820,586 | 778,718 |
| Name of Stock | End of Year Book Value | End of Year Fair Market Value |
|---|---|---|
| JP MORGAN CHASE BANK - PUBLICLY TRADED SECURITIES | 1,486,858 | 1,535,240 |
| Category/ Item | Listed at Cost or FMV | Book Value | End of Year Fair Market Value |
|---|---|---|---|
| JP MORGAN CHASE BANK - OTHER SECURITIES | AT COST | 96,422 | 96,562 |
| AMYLYX PHARMACEUTICALS | AT COST | 40,000 | 40,000 |
| AZTHERAPIES INC. | AT COST | 33,250 | 33,250 |
| COGNITIVE CLARITY | AT COST | 46,000 | 46,000 |
| ACTA PHARMACEUTICALS INC. | AT COST | 49,997 | 49,997 |
| Description | Revenue and Expenses per Books | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| INVESTMENT MANAGEMENT FEES | 8,674 | 8,674 | 0 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| FEDERAL TAX | 226 | 226 | 0 |